Compare AstraZeneca plc (AZN) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares Core S&P 500 ETF — how do they compare? AstraZeneca plc trades at $158.74 (market cap $248.14B), while iShares Core S&P 500 ETF trades at $776.59. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | IVV | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $776.81 |
52-Week Low | $147.06 | $634.93 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
IVV, tracking the S&P 500, trades at $776.38, down slightly by 0.04% amid broader market caution ahead of inflation data. The ETF shows a bullish technical signal with moving averages supporting upside, but oscillators are neutral and RSI levels indicate overbought conditions. Recent news highlights institutional interest, with First Bank & Trust increasing its stake, while JPMorgan raised its S&P 500 target to 8,000 for 2026, citing strong earnings and AI-driven growth (JPMorgan report, August 10, 2026).
Outlook remains positive due to robust corporate earnings and AI investments, but risks include high valuations and potential pullbacks from overbought levels. Investors should weigh the ETF's diversification benefits against market volatility and economic data sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
